

## **Aimmune to Present at the Wedbush PacGrow Healthcare Conference**

BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 6, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019, at 3:05 p.m. E.T. in New York City.

A live webcast of the presentation will be accessible on the Events page under the Investor Relations section of the Aimmune website at [www.aimmune.com](http://www.aimmune.com). A replay will also be available following the webcast.

### **About Aimmune Therapeutics**

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company's **C**haracterized **O**ral **D**esensitization **I**mmuno**T**herapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first investigational biologic product, AR101, is being developed as a treatment to reduce the frequency and severity of adverse events following exposure to peanut. The BLA for AR101 is under review by the U.S. FDA, which in 2015 granted AR101 Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4 to 17 years of age. In June 2019, Aimmune submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for AR101. Aimmune has filed an IND application for its second product, AR201 for the treatment of egg allergy, and intends to start a randomized phase 2 clinical trial in mid-2019. For more information, please see [www.aimmune.com](http://www.aimmune.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190806005242/en/>

Source: Aimmune Therapeutics, Inc.

#### **Investors:**

Eric Bjerkholt  
(650) 376-5582 or  
[ebjerkholt@aimmune.com](mailto:ebjerkholt@aimmune.com)

#### **Media:**

Jerica Pitts  
(312) 858-3469 or  
[jpitts@w2ogroup.com](mailto:jpitts@w2ogroup.com)

---

<https://swkhold.investorroom.com/2019-08-06-Aimmune-to-Present-at-the-Wedbush-PacGrow-Healthcare-Conference>